Phase II study of EGFR-TKI rechallenge with afatinib in advanced NSCLC patients haboring sensitive EGFR mutation without T790M
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.
- 03 Dec 2014 New trial record